Reports Q1 revenue $280.05M, consensus $270.77M. “We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion,” said Chairman and Chief Executive Officer, Michael B. Petras, Jr. “Growth was driven by disciplined execution at Sterigenics and Nordion, and Nelson Labs came in as we outlined on our fourth-quarter 2025 earnings call. Based on our first-quarter performance, we are reaffirming our 2026 outlook and remain confident in our trajectory for the remainder of the year.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health Names New CEO, Highlights Leadership Transition
- Sotera Health price target lowered to $18 from $20 at Barclays
- Sotera Health Adds Independent Director Amid Board Reshuffle
- Sotera Health appoints Kenneth Krause to board of directors
- Sotera Health Completes Large Secondary Shareholder Stock Sale